

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael J. TREUHEIT, Sheila R. O'CONNOR, Andrew A. KOSKY Docket No.: A-584-US-NP
 Serial No: 09/709,704 Group Art Unit: 1634
 Issued as: US 6,808,902 Examiner: SISSON, Bradly L.
 Filed: November 9, 2000
 For: PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN IL-1RA FC FUSION MOLECULES

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application. Documentary evidence of a chain of title from the original owner(s) to Amgen is demonstrated by:

the enclosed copy of an Assignment, the original of which is being filed for recordation by the United States Patent and Trademark Office.
 OR
 the assignment recorded in the United States Patent and Trademark Office at Reel 011305, Frames 0851-0855.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

REVOCATION OF PREVIOUS POWER OF ATTORNEY AND NEW POWER OF ATTORNEY BY ASSIGNEE

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **37500** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to Customer Number **37500**.

Respectfully submitted,

Date March 3, 2009

By

Stuart L. Watt
 Stuart L. Watt

Title: Vice President, Law

CERTIFICATE OF EFS-Web TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted to the United States Patent and Trademark Office via EFS-Web on the date indicated below:

Jae Cho

MARCH 9, 2009
 Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael J. TREUHEIT, Sheila R. O'CONNOR, Andrew A. KOSKY Docket No.: A-584-US-NP
 Serial No: 09/709,704 Group Art Unit: 1634
 Issued as: US 6,808,902 Examiner: SISSON, Bradley L.
 Filed: November 9, 2000
 For: PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN IL-1RA FC FUSION MOLECULES

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application. Documentary evidence of a chain of title from the original owner(s) to Amgen is demonstrated by:

the enclosed copy of an Assignment, the original of which is being filed for recordation by the United States Patent and Trademark Office.
 OR
 the assignment recorded in the United States Patent and Trademark Office at Reel 011305, Frames 0851-0855.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

REVOCATION OF PREVIOUS POWER OF ATTORNEY AND NEW POWER OF ATTORNEY BY ASSIGNEE

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number 37500 to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to Customer Number 37500.

Respectfully submitted,

Date March 3, 2009


By


 Stuart L. Watt

Title: Vice President, Law

CERTIFICATE OF EFS-Web TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted to the United States Patent and Trademark Office via EFS-Web on the date indicated below:


 Jae Cho

MARCH 9, 2009

Date